| 16.43 0.49 (3.07%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.72 | 1-year : | 22.13 |
| Resists | First : | 17.74 | Second : | 18.95 |
| Pivot price | 16.96  |
|||
| Supports | First : | 15.79 | Second : | 13.13 |
| MAs | MA(5) : | 16.77 |
MA(20) : | 17.19 |
| MA(100) : | 16.84 |
MA(250) : | 17.95 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 29 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 25.67 | Low : | 13.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADMA ] has closed above bottom band by 23.3%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.61 - 16.69 | 16.69 - 16.77 |
| Low: | 15.9 - 15.98 | 15.98 - 16.07 |
| Close: | 16.29 - 16.43 | 16.43 - 16.56 |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Fri, 06 Feb 2026
(ADMA) Risk Channels and Responsive Allocation - Stock Traders Daily
Thu, 05 Feb 2026
Is ADMA Biologics (ADMA) Pricing Reflect A Potential Gap To DCF And P/E Estimates - Yahoo Finance
Mon, 02 Feb 2026
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Mon, 02 Feb 2026
ADMA Biologics Inc (ADMA) Stock Analysis: Unpacking A 48% Potential Upside - DirectorsTalk Interviews
Thu, 29 Jan 2026
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views? - Finviz
Thu, 29 Jan 2026
A Look At ADMA Biologics (ADMA) Valuation After Strong Analyst Support And Growing Interest In Its Therapies - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 238 (M) |
| Shares Float | 233 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 94.2 (%) |
| Shares Short | 18,570 (K) |
| Shares Short P.Month | 18,830 (K) |
| EPS | 0.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 42.8 % |
| Operating Margin | 38 % |
| Return on Assets (ttm) | 21.7 % |
| Return on Equity (ttm) | 63.1 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 1.12 |
| Sales Per Share | 2.05 |
| EBITDA (p.s.) | 0.73 |
| Qtrly Earnings Growth | -0 % |
| Operating Cash Flow | 65 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 18.67 |
| PEG Ratio | 0 |
| Price to Book value | 9.07 |
| Price to Sales | 8 |
| Price to Cash Flow | 60.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|